Is Rexulti (brexpiprazole) safe for an adult patient with Crohn’s disease?

Rexulti Safety in Crohn's Disease

There is no specific contraindication to using Rexulti (brexpiprazole) in patients with Crohn's disease, as the FDA label does not list inflammatory bowel disease as a contraindication or precaution. However, careful consideration of the patient's overall clinical status, immunosuppression risk, and metabolic profile is essential.

Key Safety Considerations from FDA Labeling

No Direct Contraindication

• The FDA-approved prescribing information for Rexulti does not identify Crohn's disease or inflammatory bowel disease as a contraindication 1.
• The only absolute contraindication is hypersensitivity to brexpiprazole or its ingredients 1.

Relevant Warnings for Crohn's Patients

Metabolic effects that may complicate Crohn's disease management include:

• Weight gain occurred in clinical trials, with mean increases in age-and-gender adjusted body weight z-scores 1.
• Metabolic abnormalities (glucose dysregulation, lipid changes) can occur, though brexpiprazole shows relatively low incidence compared to other atypical antipsychotics 2.

Dosing adjustments may be necessary:

• Patients with moderate-to-severe hepatic impairment (Child-Pugh score ≥7) require lower maximum doses due to increased drug exposure 1.
• Patients with renal impairment (CrCl <60 mL/minute) require dose reduction 1.
• These considerations are particularly relevant as Crohn's patients may have compromised hepatic or renal function from disease complications or malnutrition 3.

Crohn's Disease-Specific Concerns

Infection Risk Context

• Crohn's disease patients are frequently on immunosuppressive therapies (anti-TNF agents, thiopurines, corticosteroids) that increase infection risk 4, 5.
• While Rexulti itself does not directly cause immunosuppression, any medication that affects overall health status warrants monitoring in immunocompromised patients 3.
• Heightened infection surveillance is advised when combining psychiatric medications with immunosuppressive Crohn's therapies 3.

Nutritional and Metabolic Interactions

• Crohn's patients frequently experience malnutrition, requiring systematic nutritional assessment 3.
• Weight gain from Rexulti could theoretically benefit malnourished patients, but metabolic monitoring remains essential 1.
• Regular malnutrition screening should assess unintended weight loss, edema, and muscle mass loss 3.

Drug-Drug Interaction Considerations

• Rexulti is metabolized by CYP2D6 and CYP3A4 enzymes 1.
• Many Crohn's medications (particularly antibiotics like metronidazole or ciprofloxacin used for perianal disease) may interact with psychiatric medications 4, 6.
• Inform all prescribers about the complete medication regimen to avoid interactions 1.

Practical Management Algorithm

Before Initiating Rexulti in Crohn's Patients:

1. Assess hepatic and renal function to determine appropriate dosing 1.
2. Review current Crohn's medications for potential drug interactions 1.
3. Establish baseline metabolic parameters: fasting glucose, lipid panel, weight, BMI 1.
4. Document nutritional status and consider dietitian involvement if malnourished 3.
5. Evaluate infection history, particularly if on immunosuppressive therapy 3.

During Treatment:

1. Monitor metabolic parameters every 3-6 months: weight, glucose, lipids 1.
2. Maintain infection surveillance with attention to fever, new symptoms, or clinical deterioration 3.
3. Coordinate care between psychiatry and gastroenterology teams 3.
4. Adjust dose if hepatic or renal function changes 1.

Common Pitfalls to Avoid

• Do not assume psychiatric medications are contraindicated simply because a patient has Crohn's disease—no evidence supports this 1.
• Do not neglect metabolic monitoring in patients already at risk for nutritional deficiencies 3, 1.
• Do not overlook drug interactions between Rexulti and antibiotics commonly used in Crohn's disease 4, 6, 1.
• Do not fail to adjust dosing in patients with hepatic or renal impairment, which may develop from Crohn's complications 1.

Evidence Quality Note

The FDA labeling provides the highest-quality safety data for Rexulti but does not specifically address Crohn's disease populations 1. Crohn's disease guidelines focus on gastrointestinal therapies and do not address psychiatric medication safety 4, 6, 7, 8. Therefore, this recommendation synthesizes general safety principles from both domains, prioritizing FDA-mandated warnings and dose adjustments while incorporating Crohn's-specific monitoring considerations from gastroenterology guidelines 3.